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Regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) might be applied for type 1 diabetes mellitus
(T1DM) treatment. Thus, we proposed in vitro assessment of adipose tissue-derived MSCs (AT-MSCs) immunomodulation on
autoimmune response along with beta cell protection in streptozotocin- (STZ-) induced diabetic C57BL/6 mice model. MSCs were
extracted from abdominal adipose tissue of normalmice and cultured to proliferate. Diabeticmice were prepared by administration
of multiple low-doses of streptozotocin. Pancreatic islets were isolated from normal mice and splenocytes prepared from normal
and diabetic mice. Proliferation, cytokine production, and insulin secretion assays were performed in coculture experiments. AT-
MSCs inhibited splenocytes proliferative response to specific (islet lysate) and nonspecific (PHA) triggers in a dose-dependent
manner (𝑃 < 0.05). Decreased production of proinflammatory cytokines, such as IFN-𝛾, IL-2, and IL-17, and increased secretion of
regulatory cytokines such as TGF-𝛽, IL-4, IL-10, and IL-13 by stimulated splenocytes were also shown in response to islet lysate or
PHA stimulants (𝑃 < 0.05). Finally, we demonstrated that AT-MSCs could effectively sustain viability as well as insulin secretion
potential of pancreatic islets in the presence of reactive splenocytes (𝑃 < 0.05). In conclusion, it seems that MSCs may provide a
new horizon for T1DM cell therapy and islet transplantation in the future.
1. Introduction
Type 1 diabetes mellitus (T1DM) is identified by the progres-
sive autoimmune destruction of pancreatic beta cells, which
results in a dramatic decrease of insulin production and con-
sequent metabolic complications. Transplantation of human
cadaveric pancreas or allogeneic islet cells could be consid-
ered therapeutic in this condition. However, the scarcity of
cadaveric pancreas donors necessitates search for alternative
cell sources [1]. In addition, replacement of the beta cell deficit
along with regulation of autoimmune response to cells that
express insulin is crucial for a T1DM definitive cure. Thus, in
recent years, the usage of cell sources that modulate immune
system along with islet cell replacement has received much
attention [2].
Mesenchymal stem cells (MSCs) represent a rare hetero-
geneous subset of multipotent stromal cells localized inmany
different adult and fetal tissues. They have self-renewal and
multidifferentiation capacity that can give rise to diverse line-
ages of mesenchymal origin, including osteoblasts, adipo-
cytes, and chondrocytes, and have also shown their potential
for differentiating into nonmesodermal origin cells [3]. Due
to these properties, MSCs might be useful in tissue regen-
eration and cell-based therapies [4]. Although multipotent
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MSCs are usually isolated from bone marrow (BM), more
recently, adipose tissue-derived MSCs (AT-MSCs) due to
more quantities, simple accessibility, and also the better
immunomodulatory properties were represented as another
alternative source for MSCs [5, 6]. Numerous recent stud-
ies indicated that MSCs possess immunomodulatory or
immunosuppressive effects both in vitro and in vivo on
several immune cells, not only T lymphocytes but also on B
lymphocytes, dendritic cells (DCs), and NK cells [7]. In vitro
studies have identified that the immunomodulatory function
of MSCs can be addressed by both cell-cell contact [8] and
soluble factors [9, 10].
MSCs can inhibit immune cells proliferation, reduce
inflammatory cytokines secretion, and alter immune cell
types to regulatory clones. They exert immune regula-
tion by the secretion of anti-inflammatory factors, such
as interleukin-10 (IL-10) [11], transforming growth factor-
𝛽 (TGF-𝛽), indoleamine 2,3-dioxygenase (IDO) [12, 13],
nitric oxide [9], prostaglandin-E2 (PGE-2) [14], and human
leukocyte antigen-G (HLA-G) [15]. In addition,MSCs induce
cell cycle arrest and apoptosis of T lymphocytes [11, 16] and
cause lymphocytes to secrete regulatory cytokines, especially
IL-10 [11].
Mesenchymal stem cells due to their low immunogenicity
and immunomodulatory properties as well as high degree of
differentiation and proliferation potential might be useful in
inhibiting the autoimmunity and regenerating the insulin-
secreting cells [17]. Furthermore, many studies declared that
the regenerative role ofMSCs could bemediated by protective
effects on functional islet cells and also differentiation potency
to insulin-producing cells in vivo and in vitro [18]. The ideal
use of MSCs in autoimmune diabetes regenerative therapy
can only be obtained after we learn their immunomodulatory
characteristics in detail. The aim of this research was to
evaluate the immunomodulatory effects of adipose-derived
MSCs on autoimmune response besides islet protective func-
tion in streptozotocin- (STZ-) induced diabetic mice model.
This study may provide some basic information regarding
application of human MSCs in treating type 1 diabetes.
2. Materials and Methods
2.1. Mice and Induction of Experimental Type 1 Diabetes.
Female inbred C57BL/6 mice (6–8 weeks old) were pur-
chased from the Pasteur Institute, Tehran, Iran. They were
given sterilized water and autoclaved standard mouse chow
throughout the study. Diabetes was induced in the mice by
intraperitoneal injection of multiple low-doses (50mg/kg,
4 consecutive days) of streptozotocin (STZ) (Sigma, USA).
STZ was solubilized in the sodium citrate buffer, pH 4.5, and
injected within 10min of preparation.
2.2. Isolation and Expansion of Adipose Tissue-Derived Mes-
enchymal Stem Cell (AT-MSCs). Abdominal adipose tissue
was taken from C57Bl/6 mice after sacrificing, washed 3
times with phosphate-buffered saline (PBS), and minced.
Extracellular matrix was digested with 0.075% type I colla-
genase (37∘C and 5% CO
2
for 30min) and centrifuged at
500 g for 5min; then the pellet was cultured in high glu-
cose Dulbecco’s modified Eagle’s medium (DMEM, GIBCO)
containing 10% fetal bovine serum (FBS, GIBCO), 2mM L-
glutamine, penicillin, and streptomycin (all from Invitrogen)
as MSCs culture media and incubated at 37∘C in 5% CO
2
.
After 48 h, nonadherent cells were removed and fresh media
were added. When adherent cells were confluent, they were
trypsinized, harvested, and expanded. All the experiments
were performed using AT-MSCs at passage 3.
2.3. Immunophenotype Analyses. The cell surface markers on
AT-MSCs were assessed usingmonoclonal antibodies against
mouse CD73, CD105, CD29, CD90, CD31, CD11b, CD45, and
CD34 (all from eBioscience).The AT-MSCs at passage 3 were
detached with 0.25% trypsin/EDTA and resuspended to 5 ×
105 cells in PBS. The cells were incubated with the specific
or isotype control antibodies (mouse IgG1-FITC and mouse
IgG1-PE, eBioscience) in 100𝜇L of 3% bovine serum albumin
(BSA, Sigma) in PBS for 1 hour at 4∘C. The cells were then
fixed with 1% paraformaldehyde (Sigma) and analyzed using
a FACS Calibur flow cytometer (BD Biosciences, San Diego,
CA) and Cyflogic software (CyFlo Ltd.).
2.4. Multilineage Differentiation. The AT-MSCs at passage 3
were analyzed for their ability to differentiate into osteoblast,
adipocyte, and chondrocyte. For osteogenic differentiation,
cells were cultured in medium containing 10mM beta-glyce-
rophosphate (Merck), 50mg/mL ascorbic acid biphosphate
(Sigma), and 100 nM dexamethasone (Sigma). After 3-week
induction, cells were stainedwith alizarin red to assessminer-
alization. For adipogenic differentiation, cells were cultured in
the presence of 250 nM dexamethasone (Sigma), 0.5mM 3-
isobutyl-1-methylxanthine (Sigma), 5mM insulin (Sigma),
and 100mM indomethacin (Sigma). After 3 weeks oil red
staining was used to determine the accumulation of oil
droplets in the cytoplasm. For differentiation to chondro-
cytes, 1 × 104 cells were centrifuged to form a pelleted
micromass and then treated with TGF-beta (10 ng/mL;
Merck), ascorbic acid biphosphate (50 𝜇g/Ml), dexam-
ethasone (10𝜇M), and insulin transferrin selenium (ITS)
(50 𝜇g/Ml; Sigma) for 3 weeks. Chondrocyte differentiation
was assessed by alcian blue staining on sections obtained
from micromasses.
2.5. Isolation of Pancreatic Islets. Pancreatic islets were iso-
lated by amodified collagenase digestionmethod [19]. Briefly,
pancreas was excised from C57BL/6 mice under sterile con-
ditions, inflated by collagenase type XI (1mg/mL; Sigma) for
few moments, and minced into small pieces. The enzymatic
digestion of the pancreatic tissue was fulfilled by collagenase
type XI in 37∘C water bath for 20min with interim agitation.
Then, digested contents were filtered through 500 and 100 𝜇m
cell strainers, respectively, to capture the islets and allow
the small exocrine cells to pass. The enriched islets were
hand picked using a sampler under a stereomicroscope. The
purified islets were counted and characterized by dithizone
(DTZ) staining. To evaluate islet cell function, islets (𝑛 =
10) were stimulated in RPMI-1640 culture solution with low
glucose (5.6mmol/L) and incubated for 4 hours at 37∘C for
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Table 1: Test and control groups in coculture experiments.
Control groups Test groups
Normal mice Diabetic mice Normal mice Diabetic mice
SP N SP D SP N + lysate SP D + lysate
SP N + PHA SP D + PHA SP N + lysate + MSCs SP D + lysate + MSCs
SP N + MSCs SP D + MSCs
SP N + PHA +MSCs SP D + PHA +MSCs
AT-MSCs
SP N: normal splenocytes; SP D: diabetic splenocytes; PHA: phytohemagglutinin; lysate: pancreatic islet cells lysate; AT-MCSs: adipose tissue-derived
mesenchymal stem cells. SP and AT-MSCs monocultures were used as blank in experiments.
detection of the total levels of insulin in the culture solution.
The RPMI-1640 culture solution was then switched to high
glucose (16.7mmol/L) and culture performed under the same
condition (37∘C, 4 hours) for insulin determination. Islet
cells lysate was prepared by freezing and thawing 10 islets in
0.5mL of RPMI-1640 medium supplemented with 10% FBS
(assuming one islet contains 1000 single cells) [20].
2.6. Splenocytes Proliferation Assay. The spleen was removed
from the normal and diabetic mice and placed in cold RPMI-
1640 media. Splenocytes were extracted using a 5mL syringe
with a 23G needle. RBC was lysed with ammonium chloride
solution and cells were washed twice. Cell suspensions were
washed in cold RPMI-1640 media and counted and viability
was assessed by 0.2% trypan blue. RPMI-1640 supplemented
with 10% heat inactivated FBS, 100mg/mL streptomycin, 100
units/mL penicillin, 2mM L-glutamine, and 10mM HEPES
was used as splenocyte culture medium. In proliferation
assay, normal and diabetic splenocytes were cocultured with
AT-MSCs in the MSCs culture mediummixed 1 : 1 with fresh
splenocyte culture medium (mixed culture medium). Prior
to final plating, optimized concentration of splenocytes
with or without phytohemagglutinin (PHA, GIBCO) was
determined at dilutions of 1, 2, 3, 4, and 5 × 105 cells in 96-well
plate byMTT assay. Final density of splenocytes was adjusted
to 2.5 × 105 cells per well for coculture with AT-MSCs.
AT-MSCs at passage 3 were harvested and adjusted to 2 ×
102/mL, 1 × 103/mL, and 5 × 103/mL inMSCs culturemedium
containing 10% FBS. A 100 𝜇L suspension of AT-MSCs was
plated into 96-well plates and incubated for 24 h at 37∘C.
After the AT-MSCs reached 70% confluence, the medium
was removed, and 100 𝜇L of fresh medium containing 5 𝜇L
of mitomycin-C (1 𝜇g/𝜇L; Sigma) was added for 1 h at 37∘C
to mitotically inactivate the AT-MSCs. After that medium
was removed and inactivated AT-MSCs were washed twice
with PBS. AT-MSCs were resuspended in 100𝜇L of mixed
culture medium, cocultured with 2.5 × 105 splenocytes, and
stimulated by 5 𝜇g/mL PHA (10 𝜇L) or 10 𝜇L of islet cells
lysate in control and test groups, respectively, for 48 h at 37∘C.
The test and control groups in proliferation experiments
were designed as in Table 1 representing the content of each
well in culture plate. Three ratios of AT-MSCs to splenocytes
were used: 1 : 50, 1 : 250, and 1 : 1250. The suppressive effect
of AT-MSCs on splenocytes proliferation in the absence
and presence of PHA (as nonspecific stimulator) and islet
cells lysate (as specific stimulator) was determined by MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide] assay. The cells, cultured in a 96-well plate, were incu-
bated for 4 h in the presence of MTT (5mg/mL; Sigma)
followed by addition of 0.1mL dimethyl sulfoxide (DMSO).
The formazan crystals were dissolved and the absorbance
was read at 570 nm by ELISA reader. The proliferation index
was calculated using the following formula:
Proliferation index
=
OD (MSCs + Splenocytes ± stimulator) −OD (MSCs)
OD (Splenocytes)
.
(1)
In order to examine the proliferation of splenocytes (in the
presence of AT-MSCs), AT-MSCs monoculture was used
as blank to subtract background absorbance of AT-MSCs.
To provide the optimum condition, the MTT assay was
repeated several times with different ratios of AT-MSCs
to splenocytes, various concentrations of PHA, and also
different periods of coculture incubation.
2.7. Cytokine Production Assay. After being trypsinized, AT-
MSCs were adjusted to 2.5 × 104/mL and plated (1mL) in 24-
well plates. After theAT-MSCs reached 70%confluence, 10 𝜇L
of mitomycin-C (1 𝜇g/𝜇L) was added into each well. After
1 h at 37∘C and 5% CO
2
, the medium was removed and cells
were washed twice with PBS. Then 12.5 × 105 splenocytes in
1mL of mixed culture medium were added and cocultured
in the presence of 50𝜇L of PHA or 50𝜇L islet lysate for
72 h at 37∘C. The groups were similar to those described for
proliferation. The supernatants of each group were collected
and evaluated by Multi-Analyte ELISArray Kit (MEM-003A,
SABiosciences) for TGF-𝛽, IL-10, IL-4, and IL-13 as regula-
tory cytokines and IFN-𝛾, IL-2, and IL-17A as inflammatory
cytokines. In order to examine cytokine production by
splenocytes, AT-MSCs were used as blank to subtract back-
ground absorbance of the cytokines produced by AT-MSCs.
2.8. Insulin Secretion Assay. AT-MSCs at passage 3 were
seeded in 96-well plates at density of 5 × 103 cells/well. After
reaching the ideal confluency, the medium was removed and
cells were washed twice with PBS. Then 2.5 × 105 normal
and diabetic splenocytes were added and cocultured with 10
freshly isolated islets (assuming one islet contains 1000 single
cells) in 100𝜇L ofmixed culturemedium (low glucose RPMI-
1640 and high glucose DMEM) supplemented with 10% FBS
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for 24 h at 37∘C. After incubation period, the medium was
removed slowly; then the islets were challenged with 100 𝜇L
stimulatorymedium containing high glucoseDMEM supple-
mented with 5mmol/L theophylline for a 10min period. The
supernatants of each group were collected and evaluated by
mouse insulin ELISA kit (EZRMI-13k,Millipore).The groups
were designed as follows: islet cells (positive control), islet
cells + normal splenocytes, islet cells + diabetic splenocytes,
islet cells + normal splenocytes + MSCs, islet cells + diabetic
splenocytes + MSCs, and splenocytes (negative control).
2.9. Statistical Analysis. All data are expressed as the mean ±
SD. Statistical analysis was done using the one-way analysis
of variance (ANOVA) to compare results. Values of 𝑃 < 0.05
were considered to be statistically significant.
3. Results
3.1. Induction of ExperimentalDiabetes. In this study, diabetic
micemodelwas developed by administration ofmultiple low-
doses of STZ. The blood glucose levels of ≥300mg/dL were
monitored within 1 week of STZ treatment. In addition, the
insulin levels of 4.95± 0.52 ng/dL in normalmice decreased to
<0.5 ng/dL in diabetic mice and pancreatic islets destruction
was confirmed by histopathological examination.
3.2. Characterization of AT-MSCs. MSCs seeded to the cul-
ture flasks sparsely and the cells displayed a fibroblast-like
morphology during the early days of incubation. After 6–
8 days, the cells gradually grew to form small colonies that
were termed colony-forming units. As growth continued,
colonies gradually expanded in size and the adjacent ones
interconnected with each other. These primary cells reached
monolayer confluence after plating for 10–12 days in their
first passages. In later passages, MSCs appeared to adopt a
uniform fibroblast-like morphology.
AT-MSCs at passage 3 were evaluated for the expression
of specific cell surfacemarkers.The cells lackedCD11b, CD34,
CD45, and CD31 whereas they were all positive for CD73,
CD90, CD105, and CD29 expression. Moreover, AT-MSCs
were able to differentiate toward osteogenic, adipogenic, and
chondrogenic lineages. After 21 days, osteogenesis of AT-
MSCs was demonstrated by mineralization of the extracellu-
lar matrix with alizarin red staining. Additionally, lipid drop-
lets were detectable by oil red O staining after three weeks
of adipocytic induction. After 21 days of induction, chondro-
genic differentiation of AT-MSCs was achieved. More than
80% of all cells stained positively with alcian blue showed the
glucose amino glycan (GAG) biosynthesis in the cell pellets
(a figure illustrating AT-MSCs characterization has been
presented as supplementary data in Supplementary Material
available online at http://dx.doi.org/10.1155/2015/878535).
3.3. Isolation of Pancreatic Islets. The perfusion of pancreas
through common bile duct is a complicated manipulation
and needs professional experience. Moreover, purification of
islets by Ficoll gradient method could have toxic side effects
on islet cells. In this study, we modified the procedure by
excluding the in situ pancreas perfusion and Ficoll gradient
steps. The islet count showed that the efficiency of isolation
varied depending on animal age and strain. The yield of
isolation was between 30 and 50 islets for each pancreas.
However, the duration of whole procedure decreased to 30–
40min for each mouse. The purified islets showed intact
morphology with smooth surface and were free of exocrine
cells as confirmed with DTZ staining. The viability of islets
was greater than 95% as determined by trypan blue.
3.4. AT-MSCs Reduce In Vitro Proliferation of Mitogen-
Stimulated Splenocytes. This experiment was designed to
investigate whether AT-MSCs could inhibit proliferation of
splenocytes that were triggered by PHA as a nonspecific
stimulator. Firstly, to assess which concentration of spleno-
cytes exerts optimized proliferation, we cultured resting cells
at dilutions of 1, 2, 3, 4, and 5 × 105 in the absence or
presence of PHA. After drawing standard curve, the final
density of normal splenocytes was adjusted to 2.5 × 105 cells
for coculture with AT-MSCs.
To evaluate antiproliferative effect of AT-MSCs, they were
added to PHA-stimulated splenocytes cultures with a ratio
of AT-MSCs to splenocytes of 1 : 50, 1 : 250, and 1 : 1250 and
cell proliferation was determined. As expected, the resting
splenocytes showed a strong proliferation response in the
presence of PHA (Figure 1; 𝑃 < 0.05), whereas addition of
AT-MSC to PHA-stimulated splenocytes resulted in a sig-
nificant reduction of splenocytes proliferation in a number-
dependent manner (Figure 1; 𝑃 < 0.05). Higher inhibition
of splenocytes proliferation was shown at the lowest dilution
tested (1 : 50). The results also indicated that AT-MSCs could
induce cell death of some splenocytes in the absence of
mitogen (Figure 1; 𝑃 < 0.05). The greater cell death of
splenocytes seemed to occur at the highest density of AT-
MSCs (1 : 50). In mitogen-induced proliferation experiment,
no significant difference was detected between normal and
diabetic splenocytes in the pattern of reduced proliferation
and response to mitogen.
3.5. AT-MSCs Exert Antiproliferative Effect on Splenocytes
Stimulated with Islet Cells Lysate. After confirming that
AT-MSCs could inhibit proliferation of mitogen-stimulated
splenocytes, we then investigated whether AT-MSCs could
inhibit proliferation of splenocytes triggered by specific stim-
ulator. AT-MSCs were cocultured with islet lysate-stimulated
splenocytes as previously described and cell proliferation
was assessed. The normal splenocytes did not proliferate
upon addition of islet lysate. In contrast, diabetic cells
showed a significant proliferation (Figure 2; 𝑃 < 0.05).
Again, the dose-dependent effect of AT-MSCs on diabetic
splenocytes proliferation inhibitionwas observed in presence
of islet lysate (Figure 2; 𝑃 < 0.05). At the lowest dilution
tested (1 : 50), more significant inhibition of splenocytes
proliferation was observed. The diabetic splenocytes did not
significantly proliferate in the absence of islet lysate. However,
the results demonstrated that AT-MSCs could induce cell
death in some of these splenocytes (Figure 2; 𝑃 < 0.05).
3.6. Effect of AT-MSCs on Cytokines Produced by Splenocytes.
To determine whether AT-MSCs modulate cytokine secre-
tion by splenocytes, we prepared a coculture design with
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Figure 1: Proliferation index of splenocytes from normal (a) and diabetic (b) mice cocultured with AT-MSCs in presence of PHA as
nonspecific stimulator. The resting splenocytes showed a sharp proliferation response in the presence of PHA. AT-MSCs caused cell death in
some resting splenocytes in the absence of mitogen (proliferation index < 1.0). AT-MSCs could suppress normal and diabetic splenocytes
proliferation in response to PHA in a dose-dependent manner, where greater concentration of AT-MSCs induced cell death in some
splenocytes (proliferation index < 1.0). Each bar represents the average of five independent experiments. ∗ indicates significant difference
between groups (𝑃 < 0.05). PHA: phytohemagglutinin; SP: splenocytes.
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Figure 2: Proliferation index of splenocytes from normal (a) and diabetic (b) mice cocultured with AT-MSCs in presence of islet cells lysate
as specific stimulator. Diabetic splenocytes showed a sharp proliferation in the presence of lysate, in which normal splenocytes remained
nonproliferated. AT-MSCs caused cell death of some resting splenocytes in the absence of lysate (proliferation index < 1.0). AT-MSCs could
suppress diabetic splenocytes proliferation in response to lysate in a dose-dependent manner, where higher concentration of AT-MSCs
induced cell death in some splenocytes (proliferation index< 1.0). Each bar represents the average of five independent experiments.∗ indicates
significant difference between groups (𝑃 < 0.05). Lysate: pancreatic islet cells lysate; SP: splenocytes.
splenocytes supplemented by PHA or islet cells lysate. Anal-
ysis of cytokines production by resting AT-MSCs showed
that they consistently secreted TGF-𝛽 and IL-6 in higher
levels compared to other cytokines (Figure 3; 𝑃 < 0.05).
As previously described, AT-MSCs were used as blank to
subtract background absorbance of their cytokines produc-
tion. The results demonstrated that addition of AT-MSCs to
lysate-stimulated diabetic splenocytes significantly decreased
IFN-𝛾, IL-2, and IL-17 production by splenocytes (Figure 4;
𝑃 < 0.05). The similar results were obtained when AT-MSCs
were added to PHA-triggered splenocytes. In addition, this
experiment indicated that AT-MSCs significantly increased
TGF-𝛽, IL-10, IL-4, and IL-13 production by splenocytes
(Figure 5; 𝑃 < 0.05). Although the increased production
of these cytokines was also observed in the presence of
PHA, increasing levels were significantly prominent in AT-
MSCs coculturedwith lysate-stimulated diabetic splenocytes,
particularly for IL-13 (Figure 5).
3.7. Protective Effect of AT-MSCs on Insulin Secretion of Islets.
To determine protective ability of AT-MSCs on islet cells
function, islets were cocultured with reactive splenocytes
and insulin content assay was performed. This experiment
indicated that the crude islets alone secreted significant
insulin levels when inducedwith stimulatorymedium (6.45 ±
0.69 ng/mL). However, diabetic splenocytes significantly
decreased insulin secretion by islets (2.59 ± 0.27 ng/mL; 𝑃 <
0.05). In contrast, coculturewithAT-MSCs led to a significant
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Figure 3: Cytokine profile secreted by AT-MSC in resting state.
AT-MSC showed higher IL-6 and TGF-𝛽 production compared to
other cytokines. Data presented the mean ± SD of five independent
experiments. Resting AT-MSCs cytokine profile was used as blank
to subtract background absorbance in coculture experiments for
cytokine assays.
improvement in insulin secretion and the viability of islet
cells (3.87 ± 0.41 ng/mL versus 2.59 ± 0.27 ng/mL; 𝑃 < 0.05)
(Figure 6).
4. Discussion
MSCs also referred to as adult multipotent stem cells rep-
resent a fibroblast-like morphology that have not only the
capacity to differentiate into several tissues, but also have
immunomodulatory and anti-inflammatory effects in vivo
and in vitro [3, 21]. In this regard, previous studies have shown
thatMSCs induce peripheral tolerance andmigrate to injured
tissues, where they can inhibit release of proinflammatory
cytokines and promote the survival of damaged cells [22–24].
It has also been reported that the underlying mechanism of
MSCs effects might be attributed by both cell-cell contact [8]
and soluble factors [9, 10].
Many studies that declared protective effects of MSCs on
islet mass and differentiation potency to insulin-producing
cells in vivo and in vitro collaborate for the application of
MSCs regenerative role in T1DM [25–27]. Although many
researchers have demonstrated the immunomodulatory
activities of MSCs, in vitro potential assays able to predict
or to correlate with therapeutic outcome of MSCs are still
partially known.Thus,we assessedin vitro immunoregulatory
effects of adipose-derived MSCs on autoimmune response
in experimental diabetic model. In this respect, we aimed at
three main goals: firstly, to evaluate suppressive effect of AT-
MSCs on autoreactive splenocytes proliferation; secondly, to
assess immunomodulatory effect of AT-MSCs on splenocytes
cytokine patterns; and finally, to evaluate protective effect of
AT-MSCs on functional islets. In the current study, MSCs
were extracted from adipose tissue of healthy C57BL/6 mice
and cultured to proliferate. Then, they were immunopheno-
typed and differentiated to osteocyte, adipocyte, and chon-
drocyte. Diabetic C57BL/6 mouse model was prepared by
administration of consecutive low-doses of STZ and diabetic
state was confirmed by serum glucose (>300mg/dL), insulin
levels, and pancreas histopathology. Pancreatic islets were
isolated from normal mice and splenocytes prepared from
normal and diabetic mice. To evaluate antiproliferative effect
of MSCs, they were cocultured with diabetic splenocytes in
the presence of islet lysate and proliferation assayed by MTT
technique. The impact of MSCs on pancreatic islet function
was assayed by insulin measurement in direct cocultures of
diabetic splenocytes with intact islets. The effect of MSCs on
cytokine patterns produced by splenocytes was assayed in
cocultured splenocytes with MSCs in the presence of islet
lysate for 72 hours. Inflammatory and regulatory cytokines
were assayed in culture media by ELISA technique.
In our study, a STZ-induced diabeticmodel was prepared.
Some strains of mice are Th1-dominant (C57BL/6, DBA/2,
AKR, and CBA), but the others are Th2-dominant strains
(BALB/c, BP2, and A/J) [28]. Many studies indicated that
pathogenesis of T1DM is an autoimmune disease mediated
byTh1-dependent inflammatory reaction [29, 30]. Therefore,
in this study the selection of C57BL/6 mice as a suitable
model for induction of autoimmune diabetes appears to be
reasonable. High doses of STZ selectively kill the insulin-
producing beta cells, whereas multiple low-doses of STZ
induce expression of glutamic acid decarboxylase (GAD)
autoantigen and develop an autoimmune response [31].
The shared immunophenotype and differential character-
istics were identified in MSCs isolated from different tissues.
Although some reports have shown that adipose-derived
MSCs due to more simple isolation and expansion and also
relative better immunomodulatory effects are a novel promise
in experimental and clinical application [5, 32], isolated AT-
MSCs had fibroblast-like morphology and differential capac-
ity that were consistent with previous studies. In addition,
analysis of cell surface markers on AT-MSCs showed a lack
of hematopoietic markers, such as CD34 and CD45, and high
expression of CD90 and CD29. However, some reports have
shown that expression of surfacemarkers onAT-MSCs varied
in different strains of mice [33].The biological characteristics
similar to bone marrow mesenchymal stem cell (BM-MSCs)
indicate that AT-MSCs may present an alternative source for
future application [34, 35].
One of the main goals in this research was close to
assessment of AT-MSCs suppressive effect on splenocytes
proliferation in the presence of specific (islet cells lysate) and
nonspecific (PHA) stimulators. The antiproliferative effects
of AT-MSCs can be summarized as follows. (1) The results
indicated that AT-MSCs in a ratio of 1 : 50, 1 : 250, and 1 : 1250
to splenocytes could inhibit stimulated splenocytes prolifera-
tion in a dose-dependent manner with the most inhibition
at the lowest dilution tested (1 : 50; 𝑃 < 0.05). However,
AT-MSCs could induce cell death in some splenocytes in
this concentration (1 : 50; 𝑃 < 0.05). The similar effects
of AT-MSCs were observed in the presence of islet lysate
and PHA. In this respect, other studies have identified that
mouse and humanMSCs harvested from different tissues can
suppress T lymphocyte proliferation stimulated by allogeneic
cells or mitogens such as PHA [10, 11, 36, 37]. In a recent
study, it has been shown that MSCs isolated from NOD
and BALB/C mice could inhibit T CD4+ proliferation in full
mismatch mixed lymphocyte reaction (MLR) assay. It has
also been clarified that, in an autoimmune fashion in vitro,
whenMSCs are added to autoreactive T CD4+ and allogeneic
dendritic cells in the presence of islet peptides, they could
significantly suppress autoreactive T CD4+ proliferation [38].
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Figure 4: The immunomodulatory effects of AT-MSCs at passage 3 on inflammatory cytokines produced by splenocytes. Addition of AT-
MSCs to islet, or PHA, stimulated splenocytes decreased IFN-𝛾, IL-2, and IL-17 production by splenocytes ((a), (b), and (c)). Background
absorbance of cytokines produced by AT-MSCs was subtracted. Thus, the representative results show splenocytes related cytokines pattern.
Data presented the mean ± SD of five independent experiments. ∗ indicates significant difference between groups (𝑃 < 0.05). SP N: normal
splenocytes; SP D: diabetic splenocytes; PHA: phytohemagglutinin; lysate: pancreatic islet cells lysate.
We found that suppressive effects of MSCs were dependent
on cell number. Several reports have demonstrated that
immunosuppressive effects of MSCs occur in a dose-related
manner in which it is considered independent of MHC
interaction [39–41]. Although target cell-MSC interactions
may be an important factor, the immunosuppressive effect
of MSCs can also be mediated through the secretion of
soluble molecules such as IL-10, TGF-𝛽, IDO, NO, PGE-
2, and HLA-G that are triggered following cross talk with
target cells [4]. (2) AT-MSCs caused some cell death in resting
splenocytes without each type of stimulators (𝑃 < 0.05). This
may suggest that MSCs can induce cellular death through
cell-cell contact as well as secretion of NO and IL-10 [9,
11]; also, they can drive splenocytes to produce IL-10 [11].
Although, in accordance with previous studies, we suggest
that MSCs may induce cell death of splenocytes rather than
cell cycle arrest [11], complementary studies are required to
identify molecular mechanisms in detail. (3) In the absence
of AT-MSCs, normal and diabetic splenocytes in response
to nonspecific stimulator (PHA) showed similar fashion. In
contrast, in response to islet lysate normal splenocytes were
not responsive, whereas a sharp proliferation was obtained in
diabetic splenocytes (𝑃 < 0.05).
In the next stage, we aimed at evaluating the effect of
AT-MSCs on cytokine patterns produced by splenocytes.
Analysis of cytokines production by AT-MSCs alone showed
that they consistently secreted TGF-𝛽 and IL-6 in higher
levels compared to other cytokines (𝑃 < 0.05). Several
publications have confirmed spontaneous secretion of
TGF-𝛽1, IL-6, hepatocyte growth factor (HGF), HLA-G, and
PGE-2 that associated with immunomodulatory properties
of MSCs [42, 43]. Our in vitro experiment showed that
AT-MSCs decreased production of IFN-𝛾, IL-2, and IL-17
and increased production of TGF-𝛽, IL-4, IL-10, and IL-13
by stimulated splenocytes in response to islet lysate or PHA
(𝑃 < 0.05). However, the increases in regulatory cytokines
were significantly prominent in AT-MSCs cocultured with
lysate-stimulated diabetic splenocytes, particularly for IL-13.
Pathogenesis of many autoimmune diseases was mediated
by several types of helper T lymphocytes (Th) such as Th1,
Th2, and Th17 identified by secretion of distinct cytokine
profiles [44]. Th1 cells produced IFN-𝛾, IL-2, and TNF-𝛼
and Th2 cells secreted IL-4, IL-5, IL-6, IL-10, and IL-13.
Regulatory T cells and Th3 cells produce TGF-𝛽 and IL10
and another T helper subtype (Th17) produces IL-17. It has
been demonstrated that MSCs have capacity to modulate
8 Journal of Diabetes Research
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Figure 5:The immunomodulatory effects of AT-MSCs at passage 3 on regulatory cytokines produced by splenocytes. AT-MSCs in coculture
with islet, or PHA, stimulated splenocytes increased TGF-𝛽, IL-10, IL-4, and IL-13 production by splenocytes ((a), (b), (c), and (d)).
Background absorbance of cytokines produced by AT-MCSs was subtracted. Therefore, the representative results show splenocytes related
cytokines pattern. Data presented the mean ± SD of five independent experiments. ∗ indicates significant difference between groups
(𝑃 < 0.05). SP N: normal splenocytes; SP D: diabetic splenocytes; PHA: phytohemagglutinin; lysate: pancreatic islet cells lysate.
immune reaction in vitro and in vivo, where they polarize
proinflammatory state to anti-inflammatory state [3]. This
is mediated by a shift in the Th1 to Th2 cell balance or
by inhibition of Th17 differentiation and IL-17 production.
Recent publications have reported the in vivo transplantation
of MSCs derived from bonemarrow and adipose tissue along
with a therapeutic approach, where they switch host immune
response towards a Th2 cytokine profile by downregulating
Th1 cytokines and/or upregulatingTh2 cytokines [22, 45–48].
Finally, in this study we used other approaches of MSCs
properties to maintain in vitro viability and functionality of
purified islets in the presence of reactive splenocytes. In this
approach, it was found that AT-MSCs in coculture design
had ability to provide islet functionality, proven by protected
insulin secretion in coculture medium (𝑃 < 0.05). Several
studies examined in vivo immunoregulatory effects of MSCs
in cotransplantation with islets, which resulted in enhancing
of islet allograft survival, insulin secretion, and sustained
normoglycemia in STZ-induced diabetic model [43, 49, 50].
In a recent study performed by Karaoz et al. coculturing of
normal and STZ-injured rat pancreatic islets with rat BM-
MSCs has improved function and viability of islets [26].
They showed that cocultivation of STZ-injured islets and
MSCs increased expression of IL-6 and TGF-𝛽1 in the culture
medium besides the expression of antiapoptotic genes. They
also demonstrated that cytoprotective, anti-inflammatory,
and antiapoptotic effects of MSCs were mediated through
paracrine actions (spontaneous production of IL-6, TGF-
𝛽1, and HGF). Furthermore, effectiveness of MSCs in pre-
vention and treatment of diabetes in NOD mice has also
been reported [38]. The protective effects of MSCs may be
dependent on both soluble mediators and also triggering of
resident tissue precursor cells in vivo [17]. However, many
studies declared that the regenerative role of MSCs could
be mediated by differentiation potential to insulin-secreting
cells in vivo and in vitro [18, 25].
In brief, we have demonstrated that AT-MSCs in a dose-
dependent manner inhibit splenocytes proliferative response
to specific and nonspecific triggers that may be mediated by
both cell-cell contact and soluble mediators such as TGF-
𝛽1 and IL-10. AT-MSCs can also polarize cytokine patterns
produced by splenocytes toward a regulatory pattern. Finally,
our results indicated that AT-MSCs through cytoprotective
and anti-inflammatory effects can effectively sustain viability
as well as insulin secretion potential of islet cells in the pres-
ence of reactive splenocytes. Although we note that adjunct
in vivo studies are required to completely investigate the
immunomodulatory functions of MSCs in autoimmune dis-
eases, this study may provide some basic information regard-
ing application of human MSCs in treating type 1 diabetes.
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Figure 6: Pancreatic islet insulin release assay. Intact islets alone
secreted distinct amount of insulin in response to stimulatory
medium (6.45 ± 0.69 ng/mL). However, the insulin secretion lev-
els decreased after coculture with diabetic splenocytes (2.59 ±
0.27 ng/mL). Interestingly, addition of AT-MSCs improved insulin
secretion by injured islets (3.87 ± 0.41 ng/mL). Data presented the
mean ± SD of five independent experiments. ∗ indicates significant
difference between groups (𝑃 < 0.05). SP N: normal splenocytes; SP
D: diabetic splenocytes; islet: mouse pancreatic islet.
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